Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine

Trevena (NASDAQ:TRVN) announced the successful completion of its first-time-in-human Phase 1 study of TRV250, a biased delta receptor agonist that the Company is developing for the treatment of acute migraine.  Preclinical data suggested that the novel selective signaling mechanism of TRV250 might avoid the seizure liability that has limited development of therapeutics targeting the delta receptor.  Data from this healthy volunteer study showed safety, tolerability, and pharmacokinetics supporting the advancement of TRV250 to Phase 2 proof of concept evaluation in patients.

As quoted in the press release:

“We are pleased that TRV250 continues to show great potential for the treatment of acute migraine,” said Maxine Gowen, President & CEO.  “Even as the treatment landscape for chronic migraine has evolved, there remains an important unmet need for patients who continue to suffer acute migraines and cannot achieve relief with currently available options.   With the exposures reached in this study without associated EEG changes, TRV250 may finally unlock the delta receptor as a therapeutic target, and we look forward to laying the groundwork for a future Phase 2 trial with this novel molecule.”

Click here to read the full press release.